Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that it plans to release financial results for the third quarter ended September 30, 2023 on November 7, 2023. The Company will host a conference call at 8:30 a.m. Eastern Time on November 7, 2023.

Participants may access the conference call via webcast on the Investors and Media page of Marinus’ website at ir.marinuspharma.com/events-and-presentations. An archived version of the call will be available approximately two hours after the completion of the event on the website.

About Marinus Pharmaceuticals  Marinus is a commercial-stage pharmaceutical company dedicated to the development of innovative therapeutics for seizure disorders. The Company first introduced FDA-approved prescription medication ZTALMY® (ganaxolone) oral suspension CV in the U.S. in 2022 and continues to invest in the potential of ganaxolone in IV and oral formulations to maximize therapeutic reach for adult and pediatric patients in acute and chronic care settings. For more information about Marinus visit www.marinuspharma.com.

Investors Jim DeNike  Senior Director, Investor Relations  Marinus Pharmaceuticals, Inc.  jdenike@marinuspharma.com

Media Molly Cameron  Director, Corporate Communications & Investor Relations  Marinus Pharmaceuticals, Inc.  mcameron@marinuspharma.com

Marinus Pharmaceuticals (NASDAQ:MRNS)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024 Marinus Pharmaceuticals 차트를 더 보려면 여기를 클릭.
Marinus Pharmaceuticals (NASDAQ:MRNS)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024 Marinus Pharmaceuticals 차트를 더 보려면 여기를 클릭.